A Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/refractory and Previously Untreated Mantle Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Acalabrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
Indications Mantle-cell lymphoma
Focus Adverse reactions; Therapeutic Use

12 Dec 2023 Results (As of July 26, 2023, n=9 of the phase I dose-finding cohort of AVO in patients with R/R MCL) assessing Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
14 Mar 2023 Planned primary completion date changed from 1 Jan 2024 to 31 Dec 2024.
08 Aug 2022 Planned number of patients changed from 41 to 53.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com